Reshaping the HIV treatment and prevention landscape
Significant improvement in R&D productivity
gsk
Improved success rates across
clinical development
~20% reduction in overall cycle
times across clinical development
Doubled the number of assets
in pivotal studies or registration
100%
80%
60%
40%
21%
58%
100%
95%
96%
20%
7%
0%
Phase I/II
Phase III/pivotal
Registration
2015-2017
-
2018 Q1 2021
Phase 3/pivotal
11
2018-Q1
2021
3.9
3.6
0.8 8.3y
22
22
14
Phase 2
31
2015-2017
5.3
4.0
1.0 10.3y
26
Phase 1
16
0
2
4
6
8
10
12
Phase 1/2
Phase 3/pivotal
Registration
2017 (Dec)
2021 (Jun)
Source: GSK 2021 benchmarking. Bars shown are composite cycle times for projects completing each development phase during the time period indicated. Early clinical cycle times are from start of Phase 1 to start of Phase 3 or pivotal Phase 2
(where Phase 2 immediately preceded filing). Any project with a pivotal start milestone from 2015-2021Q1 (for the period indicated) and any Phase 1 start milestone are captured. Pivotal cycle time captures projects with any start of pivotal Phase
2 or Phase 3 milestone and a submission milestone between 2015-2021Q1 (for the period indicated).
48View entire presentation